Our starting point is TrueMethylTM oxidative bisulfite sequencing (oxBS-Seq), a novel technology that pioneers quantitative, single-base resolution sequencing of the modified bases hydroxymethyl cytosine (5-hmC) and methylcytosine (5-mC). TrueMethyl enables analysis of the DNA methylome with unprecdented accuracy and opens new avenues for basic research, pharmaceutical discovery and diagnostics.
Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. However, traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC.
Co-invented by Prof. Shankar Balasubramanian, who previously co-invented the Solexa / Illumina sequencing-by-synthesis platform, and Michael Booth, innovative oxBS-Seq technology utilises a selective chemical oxidation that accurately distinguishes between 5-mC and 5-hmC.
TrueMethyl can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality.
Quantitative measurement of 5-hmC and 5-mC in parallel
Single-base resolution methylation and hydroxymethylation analysis
Confirmation of the location of unmethylated cytosines
CEGX is funded by Syncona Partners as well as Cambridge Enterprise and our management team comprises industry leaders and epigenetics expertise.
Company Growth (employees)
Cambridge Epigenetix was founded in 2012 and is headquartered in Great Shelford, GB